Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.
Valneva and Pfizer released data from their Phase 2 study of the Lyme disease vaccine candidate VLA15, showing strong immune response and safety profile after a second booster dose, with seroconversion rates above 90% in all age groups.
Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease vaccine, VLA15. Participants will be monitored until the end of the 2025 Lyme disease season. Marketing applications are planned for 2026.
Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil.
